TheraCryf PLC (fra:8EV) Share Price

Company Profile

Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBR
T: +44 1625315090
E: [email protected]
https://www.evgen.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,093.37	158.69	0.69%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%